EXELIOM BIOSCIENCES SAS
Business Summary
Exeliom Biosciences SAS, formerly Nextbiotix SAS, is a France-based clinical-stage biotechnology that develops therapies using components of the human gut microbiome. Its main product, EXL01, is derived from Faecalibacterium prausnitzii and is designed to influence immune responses by targeting the NOD2 pathway in macrophages. The Company is conducting clinical trials to evaluate EXL01 in areas such as cancer, Crohn’s disease, and bacterial infections.
Country of Incorporation
France
Incorporation Date
2016-12-12
Business Sector
Pharmaceuticals & Medical Research
Company Address
19 Rue De Choiseul
Get access to the below data and more business development tools by signing up for the MENA Company Data product.
- Ownership details
- Corporate structure
- Business classification
- Officers & Directors contact details
- Full company contact details
Multiply your reach by contributing your content to LSEG
LSEG contributed content reaches tens of thousands of buy and sell side professionals around the world through an integrated suite of market intelligence and transaction platforms.NEWS ON THIS COMPANY
TOP PICKS
MOST READ
MOST WATCHED
MOST POPULAR
1.
2.
3.
4.
5.
